yes agree PT3 - the company is just doing what it always said it would do and announced to market years ago - they should be supported as the professionals they are delivering on the vision they detailed to us.
those relatively new to this company may not be aware of the plan to take promising new compounds through clinical trials and then to partner for commercialisation and the share price is showing the markets reaction up near 400% in just over a year.
I guess if some feel they can second guess our teams 250+ years of professional pharma and medicine development experience without knowing what information our team has and without working in it daily, every day, all day, connected to dozens if not hundreds of industry professionals doing like works - then good On them.
i have seen the runs on the board with Kazia and I was one who was not happy with KG leaving Novogen but over time I saw a new CEO and a new strategy being explained and then results and process of delivery and daily watched the pieces coming together over 6+ years and later watched the SP turning.
i dont judge based on a few days results as these things move in cycles and trends and any cursory glance at the chart over a year shows clear direction - and it’s trends that matter
imho - you find and hire the right skilled and experienced people and you let them do their job > calls and comms are fine within limits - but it’s clear that if they have had some many or are not receptive it’s because they have higher priorities.
keeping Paxalisib in the existing trials as setup now, out licensing Cantrixil and bringing in a new drug at this time when it is EVT801 and our team is very very excited by it - then that’s a good thing and at a very low upfront cost its a better thing its and strategically prudent.
I was an advocate for Cantrixil as I saw it was very interesting and clearly so did Kazia and also so do our new partners who are very excited themselves to take it on and at a good price for both teams.
in my own profession we listen to each other as the professionals and it takes a team of us to produce our good works - so when our Kazia team licenses out Cantrixil and brings in EVT801 as the next drug - then I know they are best placed to make that call just as they have in the past.
so we can now have revenue generation from our 3 compounds:
paxalisib - in phase 3 and likely completed within 2 years and will generated hundreds of millions in milestone payments along the way through this period
cantrixil. - no more to pay, 40 million USD in milestones plus 15% in royalties and we keep it all
evt801 - going into clinic this year - and shows interest across multiple conditions - kidney, lung, liver + and has our very experienced team as excited today as it was for Paxalisib a few years ago and after 20 odd other candidates passed-over
Kazia is very well connected across the industry and the corporate heritage of our team shows depth across the industry And they have recently secured multiple streams of milestone payments whilst maintaining 90% of pax rights worldwide - so I for one will happily support Kazia’s excellent record
again, when you invest in a company you are investing in the team and we have a great team - so I will let the professionals do their good work, I trust they make the right decisionS as they have shown they do, they are the same team that delivered Paxalisib to our ownership and just wrote 400 million in licensing deals in a month and they are super excited for our new compound EVT801.
So am I and happy to say so.
